Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Afumati – page 20

363 clinical trials in Afumati, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Afumati at a glance
363
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

363 trials in Afumati

Open in trial search

Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Inhibrx Biosciences Inc.

Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Daiichi Sankyo Inc.

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Study of TX000045 for Pulmonary Hypertension in Heart Failure Patients with Preserved Ejection Fraction

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:TX000045
  • Sponsor:Tectonic Therapeutic Inc.

Study Comparing Effects and Safety of CT-P51 and Pembrolizumab with Drug Combination in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Celltrion Inc.

Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Study of single-dose oritavancin safety and tolerability in children with acute bacterial skin and skin structure infections

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Aztreonam
  • Sponsor:Melinta Therapeutics LLC

Type 2 diabetes mellitus+2

Not recruiting

Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:NNC0519-0130
  • Sponsor:Novo Nordisk A/S

Study of Subcutaneous Nivolumab for Patients with Previously Treated Advanced or Metastatic Clear Cell Kidney Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effects of Itepekimab in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Afumati

What the registry says about research in the country

01 Autoimmune Research

Innovative clinical research focusing on Systemic Lupus Erythematosus (SLE), evaluating new therapeutic approaches with ianalumab in combination with standard treatments. The trials aim to improve patient response rates and disease management outcomes.

  • SLE Treatment Development
  • Monthly Subcutaneous Therapy
  • Response Index Assessment

These studies represent significant advancement in autoimmune disease research.

02 Cardiovascular Prevention

Groundbreaking research in atherosclerotic cardiovascular disease (ASCVD) prevention, investigating inclisiran's potential in reducing major adverse cardiovascular events in high-risk patients.

  • Primary ASCVD Prevention
  • Cardiovascular Risk Reduction
  • Major Adverse Events Prevention

This research aims to establish new standards in preventive cardiology.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.